Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

Condition(s) targeted: Fanconi Anemia; Dyskeratosis Congenita

Intervention: danazol (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Children's Hospital Boston

Official(s) and/or principal investigator(s):
Colin A Sieff, MB.BCh, Principal Investigator, Affiliation: Children's Hospital Boston

Overall contact:
Colin A Sieff, MB.BCh, Phone: 617-355-2984, Email: colin.sieff@childrens.harvard.edu

Fanconi anemia (FA) and Dyskeratosis congenita (DC) are inherited bone marrow failure syndromes. The current androgen treatments (e. g., oxymetholone) used to treat FA and DC can cause unwanted masculinizing side effects, indicating a need for a different medication. Danazol is a less potent androgen,and may therefore have fewer masculinizing side effects. Danazol is currently approved by the Food and Drug Administration (FDA) for the treatment of other diseases, but it has never been studied in patients with FA and DC.

The main purpose of this study is to see if danazol is a safe treatment for FA and DC. Specifically,we would like to determine:

- the best dose of danazol;

- how fast hemoglobin (a protein that carries oxygen in the blood) levels rise in FA and

DC patients receiving danazol therapy; and

- the genetic pattern (known as expression profile) of certain cells in response to

danazol, which can predict how well people respond to the medication.

Subjects who enroll in the study will be treated with danazol for up to 24 weeks (about 6 months), and will have up to 11 study visits, including followup visits at 38 weeks (9 months) and 52 weeks (one year).

Official title: Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Toxicity associated with danazol therapy: virilization, and/or new or progressive evidence of either hepatic or renal toxicity at a Grade II level using National Cancer Institute Common Toxicity Criteria (NCI-CTC).

Secondary outcome:

The optimal dose and hematologic response rate in Fanconi anemia (FA) and Dyskeratosis congenita (DC) patients receiving danazol therapy

The gene expression profile of progenitor cells in response to danazol, both to predict responsiveness and to screen for small molecules that show a profile similar to that of responsive patients

Detailed description: Eligible patients with either Fanconi anemia (FA) or Dyskeratosis congenita (DC) will initially receive danazol at a dose of 5 mg/kg/d orally, rounded to the nearest 100 mg. For the first 8 weeks, the patient will be evaluated at weeks 2, 5, and 8 for hematologic response (HR). If the patient shows a hematological response (either a hemoglobin or platelet value no longer meeting blood cell count criteria for protocol inclusion in the absence of recent transfusions)within the first 12 weeks on the initial dose, the study drug will be continued at this dose for the next 6 weeks. If the patient fails to show any hematologic response within the first 12 weeks, the dose will be escalated to 10 mg/kg/day for the next 6 weeks, and an additional monitoring visit will be required at week 14. If at week 18, the patient fails to show any hematological response on the increased dose, the dose will be increased to 15 mg/kg/day for another 6 weeks (not to exceed 800 mg/day), and an additional monitoring visit will be required at week 20. At 24 weeks, if there is no response to this dose the patient will be taken off study drug and classified as a treatment failure, and will be monitored at weeks 38 and week 52). After week 24, if the patient continues to show a response, however, the study drug may be continued at the discretion of their primary care physician, with monitoring at weeks 38 and 52.

Should the patient lose the hematologic response on 5 or 10 mg/kg/day dosing at any point within the first 18 weeks of treatment, the dose will be escalated to 10 or 15 mg/kg/day (not to exceed 800 mg/day), respectively. The patient will continue to be evaluated at the next visit. If after week 24 no hematologic improvement is seen, the patient is then taken off study drug and monitored at weeks 38 and 52.

Minimum age: 3 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Patients must be diagnosed with FA that is documented by a positive test for increased chromosomal breakage with mitomycin C or diepoxybutane. DC patients must have clinical features consistent with the diagnosis, abnormally short lymphocyte telomeres < 1st centile by flow-FISH evaluation, or mutation in one of the known DC genes (DKC1, TERT, TERC, TINF2, NOP10, NHP2).

2. At least the following peripheral blood cytopenias: (without transfusion) Absolute neutrophil count < 500/uL or Platelet count < 30,000/uL or Hemoglobin < 8. 0 gm/dl

3. Negative pregnancy test by hCG testing, if of child-bearing potential.

4. Agreement to use a medically approved form of birth control, if of child-bearing potential.

5. Signed informed consent by the patient or legally authorized representative.

6. Patients must be either 3 years of age or > 14 kg.

Exclusion Criteria:

1. Malignancy

2. Concurrent enrollment in any other study using an investigational drug.

3. Concurrent use of anticoagulants.

4. Use of androgen therapy within last three months.

5. Patients with liver disease as defined by SGOT, SGPT or bilirubin greater than the upper limit of normal.

6. Patients with renal disease as defined by serum creatinine greater than the upper limit of normal for age.

7. Patients less than either 3 years of age or 14 kg.

8. Patients who have HLA matched sibling donors.

Colin A Sieff, MB.BCh, Phone: 617-355-2984, Email: colin.sieff@childrens.harvard.edu

Children's Hospital Boston, Boston, Massachusetts 02115, United States; Recruiting
Colin A Sieff, MB.BCh, Phone: 617-355-2984, Email: colin.sieff@childrens.harvard.edu
Pam D Boardman, MPH, Phone: 617-355-2901, Email: pamela.boardman@childrens.harvard.edu
Colin A Sieff, MB.BCh, Principal Investigator
David A Williams, MD, Sub-Investigator

Starting date: November 2009
Last updated: April 20, 2011